BDX
Becton, Dickinson and Company
NYSE · USHealthcareMedical - Instruments & Supplies
$154.48-2.33%
Price as of Jul 20, 2026
BDX growth
Becton, Dickinson and Company growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +2.4%
- EBITDA
- +0.7%
- EBIT
- +2.0%
- EPS
- -24.8%
- Free cash flow
- +21.3%
- Operating cash flow
- +18.2%
Forward estimates
- Revenue
- -8.5%
- EBITDA
- -3.5%
- EPS
- +240.4%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +4.0%
- EBIT
- +4.1%
- Net income
- -1.9%
- EPS
- -0.5%
- Free cash flow
- +17.2%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.